Brent Warner

Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY.

Hera Testing Laboratories, Inc. develops preclinical drugs for vivo and vitro toxicology. The company was founded in 2014 and is headquartered in Lexington, KY.

Vindico NanoBioTechnology LLC develops novel and life-saving therapies. The company is headquartered in San Diego, CA.

FirstMark Capital LLC (FirstMark Capital) is venture capital firm founded by Rick Heitzmann and Amish Jani in 1996. The firm is headquartered in New York.

Helomics Corp. provides cancer care development and treatment consulting services. Its products include chemoFx, biospeciFx, geneFx colon and geneFx lung. It also offers research and development services. The company was founded in 1995 and is headquartered in Pittsburgh, PA.

Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California.

Colorado BioScience Association operates as an association for life sciences. The non-profit company is based in Denver, CO. The company was founded by Steve A. Orndorff. Jennifer Jones Paton has been the CEO of the company since 2016.

Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom.

Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Zavante Therapeutics, Inc. manufactures pharmaceutical products. Its product ZOLYD is an investigational, first-in-class epoxide antibiotic with a spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients. The company was founded by Cam L. Garner, Evelyn Ellis-Grosse and Theodore R. Schroeder in 2013 and is headquartered in San Diego, CA.

Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland.

Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA.

Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ.

Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation.

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.

Hera BioLabs is a preclinical service and technology provider that offers genetic engineering and animal model creation technologies. Hera conducts all work with excellent scientific rigor and customer service at their laboratories, which include an AAALAC-accredited state-of-the-art vivarium, centrally located in Kentucky. The American company created the SRG™ rat, the first commercially available highly immunocompromised rat model validated for human tumor xenograft studies. Hera has its own proprietary genetic engineering technologies, the PiggyBac® DNA delivery system and the Cas-CLOVER™ site-specific nuclease system platforms used for cell line modification and animal model creation. The company provides researchers in industry and academia with genetic engineering technologies and related products, as well as services in these areas, performing cell engineering and in vitro and in vivo oncology studies for clients. The company was founded by Eric M. Ostertag.

Demeetra AgBio, Inc. is an American biotechnology company that specializes in gene editing. Demeetra AgBio is located in a hub for agbiotech and is centrally located in the bluegrass state. The company has built extensive gene editing know-how and has a scientific team composed of experts with diverse backgrounds in gene editing. The company's scientific achievements include being the first to successfully edit plants and yeast with their precise cas-clover technology. Demeetra AgBio's primary focus is on engineering traits for life with advanced gene-editing technologies cas-clover & piggybac transposase. The company was founded in 2019 by Eric M. Ostertag and is currently led by CEO Jack Crawford.

Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation.

Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA.